GlassScriptPhysician profile
Jody B Gray
NPI 1538462197
$3,734.50
in general payments reported to CMS, 2019-2025
30 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $683 · 2022: $514 · 2023: $265 · 2024: $1,079 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $626.12 | 2021-2025 | Farxiga, Breztri |
| Pfizer INC. | $397.10 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.43 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $293.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $203.76 | 2021-2025 | |
| Lilly USA, LLC | $138.74 | 2021-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $119.73 | 2023 | Proclaim |
| Janssen Pharmaceuticals, INC | $93.01 | 2021-2022 | |
| Exact Sciences Corporation | $85.65 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $83.71 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Inspire Medical Systems, INC. | $48.85 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $48.16 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $35.15 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $31.43 | 2021-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.32 | 2024 | Rexulti |
| Astellas Pharma US INC | $28.96 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $24.62 | 2024 | Trintellix |
| Viatris Specialty LLC | $24.40 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $23.93 | 2021 | |
| Sanofi Pasteur INC. | $21.80 | 2021 | |
| Amgen INC. | $20.46 | 2024 | Otezla, Repatha |
| Mylan Specialty L.P. | $20.04 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.37 | 2024 | Caplyta |
| Dexcom, INC. | $16.96 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.67 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $15.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.95 | 2023 | Austedo Xr |
| Axsome Therapeutics, INC. | $13.54 | 2025 | Auvelity |
| Phadia US INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.